company background image
LQDA

Liquidia NasdaqCM:LQDA Stock Report

Last Price

US$4.84

Market Cap

US$312.2m

7D

0.8%

1Y

16.6%

Updated

29 Nov, 2022

Data

Company Financials +
LQDA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

LQDA Stock Overview

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.

Liquidia Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Liquidia
Historical stock prices
Current Share PriceUS$4.84
52 Week HighUS$8.79
52 Week LowUS$3.26
Beta0.24
1 Month Change-4.35%
3 Month Change-16.12%
1 Year Change16.63%
3 Year Change14.69%
5 Year Changen/a
Change since IPO-56.40%

Recent News & Updates

Liquidia (NASDAQ:LQDA) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Oct 25
Liquidia (NASDAQ:LQDA) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Liquidia: United Manages A Temporary Win

Sep 12

Recent updates

Liquidia (NASDAQ:LQDA) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Oct 25
Liquidia (NASDAQ:LQDA) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Liquidia Corporation (NASDAQ:LQDA) Just Reported And Analysts Have Been Lifting Their Price Targets

May 15
Liquidia Corporation (NASDAQ:LQDA) Just Reported And Analysts Have Been Lifting Their Price Targets

Is Liquidia (NASDAQ:LQDA) Using Debt In A Risky Way?

Mar 16
Is Liquidia (NASDAQ:LQDA) Using Debt In A Risky Way?

Is Liquidia (NASDAQ:LQDA) Using Too Much Debt?

Sep 28
Is Liquidia (NASDAQ:LQDA) Using Too Much Debt?

Is Liquidia (NASDAQ:LQDA) A Risky Investment?

Feb 19
Is Liquidia (NASDAQ:LQDA) A Risky Investment?

What You Need To Know About Liquidia Corporation's (NASDAQ:LQDA) Investor Composition

Dec 28
What You Need To Know About Liquidia Corporation's (NASDAQ:LQDA) Investor Composition

Shareholder Returns

LQDAUS PharmaceuticalsUS Market
7D0.8%0.5%-0.9%
1Y16.6%13.0%-18.9%

Return vs Industry: LQDA exceeded the US Pharmaceuticals industry which returned 12.2% over the past year.

Return vs Market: LQDA exceeded the US Market which returned -20.5% over the past year.

Price Volatility

Is LQDA's price volatile compared to industry and market?
LQDA volatility
LQDA Average Weekly Movement9.7%
Pharmaceuticals Industry Average Movement11.0%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: LQDA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: LQDA's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200452Roger Jeffshttps://www.liquidia.com

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States.

Liquidia Corporation Fundamentals Summary

How do Liquidia's earnings and revenue compare to its market cap?
LQDA fundamental statistics
Market CapUS$312.16m
Earnings (TTM)-US$46.04m
Revenue (TTM)US$13.79m

22.6x

P/S Ratio

-6.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LQDA income statement (TTM)
RevenueUS$13.79m
Cost of RevenueUS$2.89m
Gross ProfitUS$10.90m
Other ExpensesUS$56.94m
Earnings-US$46.04m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.71
Gross Margin79.04%
Net Profit Margin-333.89%
Debt/Equity Ratio20.8%

How did LQDA perform over the long term?

See historical performance and comparison